August 30, 2016 10:25 PM ET

Biotechnology

Company Overview of CareDx, Inc

Company Overview

CareDx, Inc., a molecular diagnostics company, focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in the United States and internationally. The company’s commercialized testing solution includes the AlloMap heart transplant molecular test (AlloMap), a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. It is also developing AlloSure, a next-generation sequencing-based test to detect donor-derived cell-free DNA after transplantation. The company markets its AlloMap solution to healthcar...

3260 Bayshore Boulevard

Brisbane, CA 94005

United States

Founded in 1998

95 Employees

Phone:

415-287-2300

Fax:

415-287-2450

Key Executives for CareDx, Inc

Chief Executive Officer, President and Director
Age: 49
Total Annual Compensation: $438.5K
Chief Medical Officer and Executive Vice President
Age: 67
Total Annual Compensation: $524.5K
Chief Compliance Officer and Chief Business Officer
Age: 46
Total Annual Compensation: $445.5K
Chief Scientific Officer
Age: 66
Total Annual Compensation: $327.0K
Compensation as of Fiscal Year 2015.

CareDx, Inc Key Developments

CareDx, Inc announced delayed 10-Q filing

On 08/16/2016, CareDx, Inc announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Caredx, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016; Provides Earnings Guidance for the Year 2016

CareDx Inc. reported Unaudited consolidated earnings results for the second quarter and six months ended June 30, 2016. For the quarter, the company reported total revenue of $10,708,000 against $7,129,000 a year ago. Loss from operations was $6,849,000 against $2,886,000 a year ago. Loss before income taxes was $10,728,000 against $3,185,000 a year ago. Net loss attributable to the company was $10,335 against $3,185,000 a year ago. Net loss per basic and diluted share attributable to the company was $0.76 against $0.27 a year ago. Non-GAAP net loss was $3,945,000 against $2,632,000 a year ago. Non-GAAP basic and diluted net loss per share attributable the company was $0.29 against $0.22 a year ago. The increase in the year-over-year net loss reflects acquisition costs, acquisition related amortization of intangible assets, purchase accounting adjustments, a charge for a change in the estimated fair value of warrants, and investment in the development of AlloSure. The increase in the year-over-year non-GAAP net loss primarily reflects its investment in the development of AlloSure. For the six months, the company reported total revenue of $17,270,000 against $14,344,000 a year ago. Loss from operations was $13,418,000 against $4,277,000 a year ago. Loss before income taxes was $20,433,000 against $5,457,000 a year ago. Net loss attributable to the company was $20,087,000 against $5,457,000 a year ago. Net loss per basic and diluted share attributable to the company was $1.57 against $0.46 a year ago. Non-GAAP net loss was $8,326,000 against $4,876,000 a year ago. Non-GAAP basic and diluted net loss per share attributable the company was $0.64 against $0.41 a year ago. For the full year 2016, the company reiterates revenue guidance. The company expects fiscal 2016 revenue to grow by low- to mid-single digits on a pro forma basis over fiscal 2015 revenue, assuming that the Allenex acquisition closed on January 1, 2016. Actual reported results will only include Allenex results subsequent to the close of the acquisition on April 14, 2016, and the company expects reported revenue for the full year 2016 to be in the range of $40 million to $42 million.

CareDx, Inc to Report Q2, 2016 Results on Aug 10, 2016

CareDx, Inc announced that they will report Q2, 2016 results at 5:00 PM, Eastern Standard Time on Aug 10, 2016

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
June 15, 2016
--
Private Placement
April 12, 2016
--
Merger/Acquisition
December 16, 2015
Allenex AB (publ)
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CareDx, Inc, please visit www.caredx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.